StockData
Alnylam Pharmaceuticals, Inc. logo

Alnylam Pharmaceuticals, Inc. (ALNY) stock

ALNYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 10/3047% below fair value
$156.50−3.23 (-2.02%)

Close on Nov 17, 2026Market cap $20.96BP/E 8.1Yield –

Alnylam Pharmaceuticals EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Alnylam Pharmaceuticals's EV/EBITDA was 17.1× on Nov 11, 2026, against 176.8× a year earlier.

EV/EBITDA at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 202617.1×−137.6
2025Dec 31, 2025154.8×−44.7
2024Oct 31, 2024199.5×–

More Alnylam Pharmaceuticals figures

See a number that looks wrong?